MX2023005030A - Proteinas de fusion para el tratamiento de enfermedades. - Google Patents
Proteinas de fusion para el tratamiento de enfermedades.Info
- Publication number
- MX2023005030A MX2023005030A MX2023005030A MX2023005030A MX2023005030A MX 2023005030 A MX2023005030 A MX 2023005030A MX 2023005030 A MX2023005030 A MX 2023005030A MX 2023005030 A MX2023005030 A MX 2023005030A MX 2023005030 A MX2023005030 A MX 2023005030A
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- subject
- polypeptide
- methods
- disorder
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 8
- 201000010099 disease Diseases 0.000 title abstract 5
- 102000037865 fusion proteins Human genes 0.000 title abstract 4
- 108020001507 fusion proteins Proteins 0.000 title abstract 4
- 102000000588 Interleukin-2 Human genes 0.000 abstract 5
- 108010002350 Interleukin-2 Proteins 0.000 abstract 5
- 208000035475 disorder Diseases 0.000 abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 102000010789 Interleukin-2 Receptors Human genes 0.000 abstract 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 abstract 1
- 239000003246 corticosteroid Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
En el presente documento se describen métodos para tratar una enfermedad o trastorno en un sujeto que lo necesite, que comprenden administrar al sujeto una o más dosis de una proteína de fusión de interleucina 2 (IL2), en donde la dosis es de aproximadamente 0,1 mg a aproximadamente 9 mg. También se describen aquí métodos para tratar una enfermedad o trastorno en un sujeto que lo necesite, que comprenden administrar al sujeto una dosis de una proteína de fusión de IL2, en donde la dosis es superior a aproximadamente 9 mg. Las proteínas de fusión de IL2 usadas en los métodos descritos en el presente documento comprenden: (a) un primer polipéptido que comprende un polipéptido de IL2; y (b) un segundo polipéptido que comprende un dominio extracelular de un polipéptido del receptor alfa de IL2 (IL2Ra). En algunos aspectos, la enfermedad o trastorno es una enfermedad inmune mediada, como el lupus eritematoso sistémico. En algunos aspectos, los métodos administran además un corticosteroide al sujeto.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063198615P | 2020-10-29 | 2020-10-29 | |
| US202063123991P | 2020-12-10 | 2020-12-10 | |
| PCT/US2021/057352 WO2022094275A1 (en) | 2020-10-29 | 2021-10-29 | Fusion proteins for the treatment of disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023005030A true MX2023005030A (es) | 2023-05-16 |
Family
ID=78771208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023005030A MX2023005030A (es) | 2020-10-29 | 2021-10-29 | Proteinas de fusion para el tratamiento de enfermedades. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240325495A1 (es) |
| EP (1) | EP4236962A1 (es) |
| JP (1) | JP2023548311A (es) |
| KR (1) | KR20230097094A (es) |
| AU (1) | AU2021369823A1 (es) |
| CA (1) | CA3195260A1 (es) |
| CL (1) | CL2023001183A1 (es) |
| IL (1) | IL302114A (es) |
| MX (1) | MX2023005030A (es) |
| WO (1) | WO2022094275A1 (es) |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| DZ2788A1 (fr) | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
| AU2002355955A1 (en) | 2001-08-13 | 2003-03-03 | University Of Southern California | Interleukin-2 mutants with reduced toxicity |
| ATE497783T1 (de) | 2003-05-06 | 2011-02-15 | Syntonix Pharmaceuticals Inc | Gerinnungsfaktor vii-fc chimäre proteine zur behandlung von hämostatischen krankheiten |
| US7348004B2 (en) | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
| WO2005007121A2 (en) | 2003-07-18 | 2005-01-27 | Massachusetts Institute Of Technology | Mutant interleukin-2(il-2) polypeptides |
| KR20070003934A (ko) | 2004-03-05 | 2007-01-05 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템 |
| US8906356B2 (en) | 2007-11-05 | 2014-12-09 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
| DE102008023820A1 (de) | 2008-05-08 | 2009-11-12 | Aicuris Gmbh & Co. Kg | Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen |
| CA2749539C (en) | 2009-01-21 | 2022-07-19 | Amgen Inc. | Compositions and methods comprising interleukin-2 mutants for treating inflammatory and autoimmune diseases |
| CU23734A1 (es) | 2009-11-27 | 2011-11-15 | Centro Inmunologia Molecular | Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas |
| UA117294C2 (uk) | 2011-02-10 | 2018-07-10 | Рош Глікарт Аг | Імунокон'югат |
| US9580486B2 (en) | 2013-03-14 | 2017-02-28 | Amgen Inc. | Interleukin-2 muteins for the expansion of T-regulatory cells |
| SI3102595T1 (sl) | 2014-02-06 | 2019-02-28 | F. Hoffmann-La Roche Ag | Fuzijske beljakovine z interlevkinom-2 in njihova uporaba |
| IL289475B2 (en) | 2014-07-21 | 2023-10-01 | Delinia Inc | Molecules that activate T cells are selectively regulated for the treatment of autoimmune diseases |
| EP3482766B1 (en) | 2014-08-11 | 2020-05-20 | Delinia, Inc. | Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
| CN115073581A (zh) | 2016-05-04 | 2022-09-20 | 美国安进公司 | 用于扩增t调节性细胞的白细胞介素-2突变蛋白 |
| CN110167957A (zh) | 2016-11-08 | 2019-08-23 | 德里尼亚公司 | 用于治疗自身免疫疾病的il-2变体 |
| CU24483B1 (es) | 2016-11-15 | 2020-04-02 | Ct Inmunologia Molecular | Método para incrementar los niveles de secreción de la interleucina-2 |
| CA3094112A1 (en) | 2018-03-28 | 2019-10-03 | Bristol-Myers Squibb Company | Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use |
-
2021
- 2021-10-29 EP EP21815018.3A patent/EP4236962A1/en active Pending
- 2021-10-29 IL IL302114A patent/IL302114A/en unknown
- 2021-10-29 CA CA3195260A patent/CA3195260A1/en active Pending
- 2021-10-29 WO PCT/US2021/057352 patent/WO2022094275A1/en active Application Filing
- 2021-10-29 US US18/251,214 patent/US20240325495A1/en active Pending
- 2021-10-29 KR KR1020237017607A patent/KR20230097094A/ko unknown
- 2021-10-29 JP JP2023526282A patent/JP2023548311A/ja active Pending
- 2021-10-29 MX MX2023005030A patent/MX2023005030A/es unknown
- 2021-10-29 AU AU2021369823A patent/AU2021369823A1/en active Pending
-
2023
- 2023-04-26 CL CL2023001183A patent/CL2023001183A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021369823A1 (en) | 2023-06-01 |
| CA3195260A1 (en) | 2022-05-05 |
| US20240325495A1 (en) | 2024-10-03 |
| CL2023001183A1 (es) | 2023-09-29 |
| EP4236962A1 (en) | 2023-09-06 |
| JP2023548311A (ja) | 2023-11-16 |
| AU2021369823A9 (en) | 2024-10-03 |
| KR20230097094A (ko) | 2023-06-30 |
| IL302114A (en) | 2023-06-01 |
| WO2022094275A1 (en) | 2022-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hsu et al. | A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy | |
| CN110475571B (zh) | 细胞免疫疗法前细胞毒性预调理的替代 | |
| Desbois et al. | IL-15 trans-signaling with the superagonist RLI promotes effector/memory CD8+ T cell responses and enhances antitumor activity of PD-1 antagonists | |
| Hemmerle et al. | The antibody‐based targeted delivery of interleukin‐4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer | |
| Todd et al. | Interferon-gamma induces HLA-DR expression by thyroid epithelium. | |
| JP5680661B2 (ja) | Ｉｌ−２に由来する免疫調節ポリペプチド並びに癌及び慢性感染症の治療におけるその使用 | |
| Mazor et al. | Tolerogenic nanoparticles restore the antitumor activity of recombinant immunotoxins by mitigating immunogenicity | |
| CY1117387T1 (el) | ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ | |
| Chen et al. | NK cytolysis is dependent on the proportion of HLA-G expression | |
| Czikora et al. | Epithelial sodium channel-α mediates the protective effect of the TNF-derived TIP peptide in pneumolysin-induced endothelial barrier dysfunction | |
| Hebb et al. | Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression | |
| Sun et al. | Macrophage STING signaling promotes NK cell to suppress colorectal cancer liver metastasis via 4-1BBL/4-1BB co-stimulation | |
| Holden et al. | Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents | |
| Hopkins et al. | Monoclonal antibodies to sheep lymphocytes. I. Identification of MHC class II molecules on lymphoid tissue and changes in the level of class II expression on lymph-borne cells following antigen stimulation in vivo. | |
| JPS5852225A (ja) | 脱髄疾患治療剤 | |
| Sun et al. | Comparable therapeutic potential of umbilical cord mesenchymal stem cells in collagen-induced arthritis to TNF inhibitor or anti-CD20 treatment | |
| Bernabei et al. | IGF-1 down-regulates IFN-γR2 chain surface expression and desensitizes IFN-γ/STAT-1 signaling in human T lymphocytes | |
| JP2022065088A (ja) | Ｃｌｅｖｅｒ－１、ｔｎｆ－アルファおよびｈｌａ－ｄｒ結合剤を用いた免疫活性化の診断 | |
| Zhuang et al. | Robo4 vaccines induce antibodies that retard tumor growth | |
| MX2022009100A (es) | Proteinas de fusion fc heterodimericas il15/il15r alfa para el tratamiento de cancer. | |
| Corbellari et al. | The immunocytokine L19-TNF eradicates sarcomas in combination with chemotherapy agents or with immune check-point inhibitors | |
| Vahouny et al. | Thymosin peptides and lymphokines do not directly stimulate adrenal corticosteroid production in vitro. | |
| WO2021068196A1 (en) | Methods of using il-33 protein in treating cancers | |
| Chabab et al. | IL-21 signaling in the tumor microenvironment | |
| Ma et al. | EGFRvIII-specific CAR-T cells produced by piggyBac transposon exhibit efficient growth suppression against hepatocellular carcinoma |